Wide Ranks

KALV

KalVista Pharmaceuticals, Inc.

10.09

Top Statistics
Market Cap 496 M Forward PE -4.85 Revenue Growth 0.00 %
Current Ratio 8.55 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.73 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 174 M Total Cash Per Share 4.03 Total Debt 6 M
Total Debt To Equity 3.62 Current Ratio 8.55 Book Value Per Share 4.01
All Measures
Short Ratio 2375.00 % Message Board Id finmb_136678928 Fax 866 553 3269
Shares Short Prior Month 6 M Return On Equity -0.9084 City Cambridge
Uuid 855accb6-3648-3882-a18c-cf430f76475f Previous Close 9.98 First Trade Date Epoch Utc 1 B
Book Value 4.01 Beta 0.9130 Total Debt 6 M
Volume 151876 Price To Book 2.52 Last Split Date 1 B
Fifty Two Week Low 7.39 Total Cash Per Share 4.03 Shares Short Previous Month Date 1 B
Target Median Price 31.50 Max Age 86400 Sand P52 Week Change 0.3133
Target Mean Price 29.17 Net Income To Common -141770000 Short Percent Of Float 0.1693
Implied Shares Outstanding 49 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 541250 Average Volume10days 541250 Total Cash 174 M
Next Fiscal Year End 1 B Held Percent Insiders 0.0135 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 9.98
Target Low Price 18.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 10.98
Open 10.08 Free Cashflow -57843376 State MA
Dividend Yield 0.00 % Return On Assets -0.5394 Time Zone Short Name EST
Trailing Eps -3.57 Day Low 9.95 Address1 55 Cambridge Parkway
Shares Outstanding 49 M Price Hint 2 Target High Price 39.00
Website https://www.kalvista.com 52 Week Change 0.1955 Average Volume 415592
Forward Eps -1.87 Recommendation Key none Compensation As Of Epoch Date 1 B
Quick Ratio 832.50 % Last Split Factor 1:14 Regular Market Day High 10.27
Is_sp_500 False Profit Margins 0.00 % Debt To Equity 3.62
Fifty Two Week High 16.88 Day High 10.27 Shares Short 7 M
Regular Market Open 10.08 Industry Key biotechnology Earnings Growth 0.00 %
Revenue Growth 0.00 % Shares Percent Shares Out 0.1498 Operating Cashflow -102721000
Currency USD Time Zone Full Name America/New_York Market Cap 496 M
Is_nasdaq_100 False Zip 02142 Quote Type EQUITY
Industry Biotechnology Long Name KalVista Pharmaceuticals, Inc. Regular Market Day Low 9.95
Held Percent Institutions 1.10 Current Price 10.09 Address2 Suite 901 East
Enterprise To Ebitda -1.73 Financial Currency USD Current Ratio 8.55
Industry Disp Biotechnology Number Of Analyst Opinions 6 Country United States
Float Shares 24 M Two Hundred Day Average 12.04 Enterprise Value 268 M
Forward PE -4.85 Regular Market Volume 151876 Ebitda -154720000
Exchange NGM
Go to Yahoo Finance Go to Seeking Alpha 
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.

The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial.

In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks.

The company is headquartered in Cambridge, Massachusetts.